The addition of α-PD1 did significantly improve performance of the NLRP3 agonist in combination with 5Gy XRT in both tumor models (P = 0.017 and P < 0.0001, respectively, supplementary figure S1e and S1f); however, α-PD1 did not boost the strength of 12Gy XRT + NLRP3 combination in regards to primary tumors (all P > 0.05, Fig. 1d, e). The gene discussed is NLRP3; the disease is neoplasm.